Biomerica rises after securing first major European order for stomach infection test

Shares of diagnostics maker Biomerica BMRA.O rise 8.2% to $2.25 premarket

Co says it secured its first commercial European order for its Hp Detect stool test from one of Europe’s largest lab chains

Test detects H. pylori, a common stomach bacteria that can cause ulcers and stomach cancer and is hard to treat due to antibiotic resistance - BMRA

Order is for the UK market and follows approval from the UK medicines regulator in February, co says

Adds the lab chain’s wide reach could help expand sales across Europe and lead to repeat orders as testing becomes routine

Says H. pylori affects about 45% of people in Europe’s five biggest countries

BMRA rose ~5% in 2025